Slide 1: Formycon AG – The Biosimilar Experts
Formycon AG The Biosimilar Experts October 2025
Slide 2: Disclaimer
Disclaimer This presentation may contain forward-looking statements and information which are based on our current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial si
Slide 3: Skillset and mindset are our key ingredients
Skillset and mindset are our key ingredients Pure Play Biosimilar 250 employees from more Combining high professional Formycon's pipeline Company – established 2012 than 30 different countries. expertise in biopharma- includes three approved in Munich, Germany. ceutical development with biosimilars,
Slide 4: We are acting along a clear mission
We are acting along a clear mission Biosimilars open up enormous opportunities Contributing to ease Improving the financial strains on the patient access to vital world’s healthcare systems medicines 4 Formycon FormyconAG AG– //The TheBiosimilar BiosimilarExperts Experts
Slide 5: Huge Biosimilar target opportunities
Huge Biosimilar target opportunities 39 Blockbuster drugs with an expected global sales volume of more than 190 USD billion will lose their exclusivity in the coming years, creating huge opportunities for Biosimilars Year Number of blockbuster drugs losing exclusivity Cumulative global annual peak s
Slide 6: The Biosimilar market develops very dynamically
The Biosimilar market develops very dynamically Global Biosimilar Sales 2016 – 2030 USD billion* 74.0 2015 – 2021 2021 – 2025 RoW CAGR 39% RoW CAGR 16% US CAGR 97% US CAGR 26% Europe CAGR 48% Europe CAGR 8% Biosimilars is the ● ROW fastest growing segment ● US 33.0 ● EUROPE in Pharma. The US market
Slide 7: Maximizing our assets along a clear path
Laser Focus on Pipeline Execution and commercial Growth Maximizing our assets along a clear path 2024 2025 Important year with Further Achieving many operational transformation and growing milestones into a commercial sustainable successfully company with profitability with achieved two products on
Slide 8: Strong operational H1 with multiple Achievements – H2 Outlook with further Milestones
Strong operational H1 with multiple Achievements – H2-Outlook with further important Milestones ahead H1 2025 H2 2025 2026 • Approvals in Brazil and FYB201 • Launch of Pre-filled • Expansion into further Ophthalmology partnership Africa/Subsahara Syringe in Europe markets Lucentis® biosimilar • PFS
Slide 9: Strong maturing and growing pipeline
Strong maturing and growing pipeline Diversified portfolio of commercial, late and mid stage programs Lucentis® 50% Further approvals Ophthalmology $1,2bn (Genentech Inc.) owned and launches 2022 US* ex-US MENA Brasilien Subsahara- Afrika Stelara® Fully Further Immunology $10.4bn (Johnson & Johnson)
Slide 10: Lucentis Biosimilar FYB201 – Strong Presence across the World
Lucentis® Biosimilar FYB201 – Strong Presence across the World FYB201/ranibizumab so far launched in 21 Countries Growth drivers ● Introduction of Prefilled Syringe in European Markets ● Entering additional Markets globally ● Further Lifecycle Management Optimizations ● Prepare for strong Re-entry i
Slide 11: Stelara Biosimilar FYB202 – first Patients treated with Otulfi
Stelara® Biosimilar FYB202 – first Patients treated with Otulfi® FYB202/ustekinumab launched in the US, Europe and Canada Growth drivers ● Build Momentum in US and EU ● Add. Launches globally, e.g. CA, UK ● Further LCM Optimizations Fymskina® Formycon Income Position ● 2023 & 2024: Milestone payment
Slide 12: Eylea Biosimilar FYB203 – approved in US, EU and UK
Eylea® Biosimilar FYB203 – approved in US, EU and UK FYB203/aflibercept waiting in the wings Growth drivers ● Commercial Partnerships ● International Approvals ● Preparing Supply Chain in Accordance with IP Landscape FYB203 approved Further potenti al Eylea® is a registered trademark of Regeneron Ph
Slide 13: FYB206 – Keytruda Biosimilar Candidate in the leading Group
FYB206 – Keytruda® Biosimilar Candidate in the leading Group Targeted Reference Indications Achievements and next important Milestones Immuno-oncology: Melanoma (black skin cancer), ● Patient enrollment for clinical development completed non-small cell Lung Cancer, classical Hodgkin’s Lymphoma (Last
Slide 14: 2025 outlook – Guidance confirmed
2025 outlook – Guidance confirmed Guidance Adjusted Working Guidance 2025 Revenue EBITDA 2025 EBITDA Capital Revenue: 55 to 65 -20 to -10 -20 to -10 55 to 65 ● H1 revenue as expected, major revenue streams expected for Q4 2025 € million € million € million € million EBITDA: ● For Full Year expected
Slide 15: Formycon – stable Anchor Investors and increased Liquidity
Formycon – stable Anchor Investors and increased Liquidity Bond: ISIN / WKN: NO0013586024 / A4DFJH Shareholder Structure **per definition of Deutsche Börse Stock market: 24.04 % Santo Holding (Deutschland) GmbH 13.25 % Wpart GmbH, Wen.Co Invest GmbH, Peter Wendeln − ISIN / WKN: DE000A1EWVY8 / A1EWVY
Slide 16: Fully focused Pure-Play Biosimilar Company
Fully focused Pure-Play Biosimilar Company WE CREATED WE HAVE all ingredients to WE ACT in a highly WE ARE entering the next a strong Platform with successfully fulfill our attractive market stage of the Formycon track record mission Growth Story 16 Formycon AG // The Biosimilar Experts
Slide 17: Formycon AG
Formycon AG Formycon AG Fraunhoferstr. 15 82152 Planegg-Martinsried Germany + 49 89 864 667 100 info@formycon.com www.formycon.com 17 Formycon AG // The Biosimilar Experts